scispace - formally typeset
Search or ask a question
Author

Fuller Rw

Bio: Fuller Rw is an academic researcher. The author has contributed to research in topics: Substrate (chemistry) & Monoamine oxidase. The author has an hindex of 1, co-authored 1 publications receiving 13 citations.

Papers
More filters

Cited by
More filters
Book ChapterDOI
TL;DR: In subjects with Parkinson's disease the MAO-B inhibitor L-deprenyl exerts a L-dopa-sparing effect, prolongs L- dopa action and seems to have a favorable influence regarding on-off disabilities.
Abstract: The development of monoamine oxidase (MAO) inhibitors has followed a winding path. At the origin was the finding of E. A. Zeller that iproniazid, a hydrazine derivative designed to improve the tuberculostatic action of isoniazid, caused potent inhibition of MAO in vitro and in vivo. The inhibitor also exerted in vivo activity in the brain, subsequent pharmacological research indicating that this inhibition led to changes of cerebral functions [1]. Although the drug had no overt behavioral effects in animals when given alone, it modified the action of reserpine, one of the first modern psychotropic drugs. Thus, administration of iproniazid prior to reserpine unexpectedly antagonized the decreases in locomotor activity and in 5-hydroxy-tryptamine (5 HT) levels induced by reserpine in the brain, the animals sometimes even showing locomotor stimulation [1]. Since one serious side effect of reserpine in man was known to be mental depression, the antagonism of reserpine by iproniazid hinted at the possibility that this drug might be of use in the treatment of mood disorders. However, the actual breakthrough for the development of iproniazid as an antidepressant came from clinical observations. Various investigators had reported psychostimulant side effects of the MAO inhibitor in patients with tuberculosis and other chronic diseases.

175 citations

Journal ArticleDOI
TL;DR: The biogenic amines norepinephrine, dopamine and serotonin have been shown to be highly localized in specific neurones within the mammalian brain s,29 and evidence is added to the hypothesis that each amine must play a different role in the central nervous system.

63 citations

Journal ArticleDOI
TL;DR: Lower platelet MAO activities have been reported in schizophrenia, bipolar affective disorders, alcoholism, cycloid psychoses, attention deficit disorder in children, epilepsy, insulin-dependent diabetes, Lesch-Nyhan syndrome, migraine headache, iron deficiency anemia, riboflavin deficiency, Down's syndrome, toxemia of pregnancy and thyrotoxicosis.

59 citations

Journal ArticleDOI
TL;DR: Dopaminergic indices were associated with ADHD symptom severity (Conners-ATRS) and noradrenergic indices with CPT performance and support a multisystem dysfunction underlying ADHD pathophysiology.

34 citations

Journal ArticleDOI
TL;DR: The potentials of MAO inhibitors in the treatment of mental depression and other disorders may need to be re-assessed in light of current knowledge.
Abstract: 1. 1. Inhibitors of monoamine oxidase (MAO) may show a high degree of selectivity toward various MAO forms or toward the enzyme in specific tissues or cells. The combination of selective inhibitors with other drugs or with amines or amine precursors may further enhance their selectivity. 2. 2. Most MAO inhibitors in clinical use were introduced before this selectivity and its bases were well understood, and little systematic effort appears to have been directed toward development of MAO inhibitors with optimum therapeutic benefit and minimum side effects based on selective actions. The potentials of MAO inhibitors in the treatment of mental depression and other disorders may need to be re-assessed in light of current knowledge.

19 citations